<DOC>
	<DOCNO>NCT00811018</DOCNO>
	<brief_summary>This multi-center , open-label study sitaxsentan sodium 100 mg take orally daily subject PAH sitaxsentan , particular country region , commercially available treatment PAH study close .</brief_summary>
	<brief_title>A Long-Term , Open-Label Study Evaluate Safety Sitaxsentan Sodium Treatment Patients With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description>Open-label extension</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Sitaxsentan</mesh_term>
	<criteria>Diagnosis Pulmonary Arterial Hypertension ( PAH ) confirm cardiac catheterization . Current diagnosis WHO group 1 PAH functional class 2 , 3 , 4 symptom . Has portal hypertension chronic liver disease . Has history leave sided heart disease significant cardiac disease .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Open-label study</keyword>
</DOC>